Suppression of cellular immunity by head and neck irradiation. Precipitating factors and reparative mechanisms in an experimental model.
Gray. W C WC; Hasslinger. B J BJ; Suter. C M CM; Blanchard. C L CL; Goldstein. A L AL; Chretien. P B PB
Key Findings
- Head and neck irradiation in mice sharply lowers immune responses like delayed‑type hypersensitivity and lymphocyte counts.
- Thymosin‑alpha‑1 treatment restores these immune measures, often to levels above non‑irradiated controls.
- The restorative effect is stronger for head/neck radiation than pelvic radiation, and only works within a limited dose window.
Practical Outcomes
- For biohackers, Tα1 could be explored as an immune‑boosting supplement after severe stress or radiation exposure, but human data are missing. Any use should start at low doses and be monitored closely, and the peptide is not a proven everyday performance enhancer.
Summary
In mice, radiation to the head and neck weakens the immune system, but giving the peptide thymosin‑alpha‑1 (Tα1) brings immune markers back up, sometimes even higher than normal. The same peptide works less well when only the pelvis is irradiated, and the effective dose range is narrow, meaning you have to be careful about how much you use. The study suggests Tα1 might help restore immunity after radiation, but it’s still early animal work.
Abstract
A model was developed in C3H mice to investigate the immunosuppressive effects of head and neck irradiation and to explore mechanisms for repair of the defects. Mice receiving 1200 rad (12 Gy) of head and neck irradiation showed significant depression of delayed-type hypersensitivity, peripheral blood lymphocyte counts, spleen cell counts, and spleen cell production of interleukin-2. Treatment with optimal dosages of thymosin alpha 1 (T alpha-1) produced significant increases in all of these values, in some instances to levels higher than in the nonirradiated controls. In identical experiments with mice irradiated to a portal limited to the pelvic region, T alpha-1 induced only partial remission of the abnormalities. The dose response of T alpha-1 with head and neck irradiation showed a relatively limited dose range for immune restoration, a finding that warrants similar determinations in clinical trials with immunomodulating agents. The results suggest a potential clinical usefulness of T alpha-1 and also interleukin-2 in restoring cellular immunity after irradiation for head and neck cancers. The model appears to be useful for investigating immunomodulating agents before they are clinically evaluated as adjuvants with head and neck irradiation regimens.
Study Information
pubmed
1986
10.1001/archotol.1986.03780110061008